Table 51Meta-analysis comparing adverse events of sitagliptin 100 mg to placebo

OutcomeNHeterogeneity
MeasureEstimate95% CIP valueI2
Total7aRR0.6320.523, 0.763<0.0010%
Due to adverse event7aRR0.880.544, 1.4320.6140%
Hypoglycemia7aRR1.260.488, 3.250.630%
Infections3bRR1.060.663, 1.6940.8080%
Nausea4cRR1.400.497, 3.9620.520%
Vomiting3dRR0.7650.203, 2.8790.6920%
Total cholesterol3eWMD2.03−5.6, 9.60.60154.9%
HDL7fWMD0.003−1.38, 1.380.99757.8%
LDL7fWMD0.13−2.62, 2.880.9271.4%
Triglycerides7fWMD−9.97−19.4, −0.490.0395.7%
a

Studies included in analysis: Aschner (2006), Nonaka (2007), Raz(2006), Mohan (2009), Hanefeld(2007), Scott(2007), Goldstein(2007).

b

Studies included in analysis: Aschner (2006), Raz (2006), Mohan (2009).

c

Studies included in analysis: Aschner (2006), Raz (2006), Mohan (2009), Goldstein (2007).

d

Studies included in analysis: Aschner (2006), Raz (2006), Goldstein (2007).

e

Studies included in analysis: Charbonnel (2006), Hanefeld (2007), Scott (2007)

f

Studies included in analysis: Charbonnel (2006), Hanefeld (2007), Scott (2007), Aschner (2006), Raz (2006), Goldstein (2007), Mohan (2009)

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.